Allogene Therapeutics, Inc.
ALLO
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The companā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.88
Price-4.57%
-$0.09
1Y
Price
Market Cap
$648.891m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-100.0%
1y CAGR-72.0%
3y CAGR-78.9%
5y CAGREarnings
-$173.760m
+17.7%
1y CAGR+14.3%
3y CAGR-11.0%
5y CAGREPS
-$0.77
+25.8%
1y CAGR+24.9%
3y CAGR-0.7%
5y CAGRBook Value
$278.875m
$395.958m
Assets$117.083m
Liabilities$81.051m
DebtDebt to Assets
20.5%
-0.4x
Debt to EBITDAFree Cash Flow
-$109.526m
+20.9%
1y CAGR+10.3%
3y CAGR+5.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company